Arcus Biosciences, Inc. financial data

Symbol
RCUS on NYSE
Location
Hayward, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 28 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 446% % -12%
Return On Equity -68% % -50%
Return On Assets -31% % -40%
Operating Margin -156% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 107,973,536 shares 18%
Common Stock, Shares, Outstanding 107,100,000 shares 17%
Entity Public Float $825,139,210 USD -23%
Weighted Average Number of Shares Outstanding, Basic 106,500,000 shares 17%
Weighted Average Number of Shares Outstanding, Diluted 106,500,000 shares 17%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $240,000,000 USD -46%
Revenue from Contract with Customer, Excluding Assessed Tax $45,000,000 USD -14%
Research and Development Expense $503,000,000 USD 14%
General and Administrative Expense $112,000,000 USD -7.4%
Operating Income (Loss) $375,000,000 USD -18%
Nonoperating Income (Expense) $35,000,000 USD -29%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $340,000,000 USD -26%
Income Tax Expense (Benefit) $1,000,000 USD 0%
Net Income (Loss) Attributable to Parent $341,000,000 USD -26%
Earnings Per Share, Basic -3 USD/shares -10%
Earnings Per Share, Diluted -3 USD/shares -10%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $238,000,000 USD 18%
Assets, Current $857,000,000 USD -24%
Property, Plant and Equipment, Net $42,000,000 USD -12%
Operating Lease, Right-of-Use Asset $65,000,000 USD -29%
Other Assets, Noncurrent $65,000,000 USD -13%
Assets $974,000,000 USD -22%
Accounts Payable, Current $42,000,000 USD 223%
Employee-related Liabilities, Current $28,000,000 USD 3.7%
Contract with Customer, Liability, Current $52,000,000 USD -50%
Liabilities, Current $235,000,000 USD 9.3%
Contract with Customer, Liability, Noncurrent $53,000,000 USD -82%
Operating Lease, Liability, Noncurrent $99,000,000 USD -10%
Other Liabilities, Noncurrent $152,000,000 USD 12%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,000,000 USD
Retained Earnings (Accumulated Deficit) $1,379,000,000 USD -33%
Stockholders' Equity Attributable to Parent $436,000,000 USD -23%
Liabilities and Equity $974,000,000 USD -22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $132,000,000 USD -6500%
Net Cash Provided by (Used in) Financing Activities $142,000,000 USD -38%
Net Cash Provided by (Used in) Investing Activities $32,000,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 107,100,000 shares 17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $42,000,000 USD -28%
Deferred Tax Assets, Valuation Allowance $316,000,000 USD 36%
Deferred Tax Assets, Gross $330,000,000 USD 30%
Operating Lease, Liability $111,000,000 USD -8.3%
Payments to Acquire Property, Plant, and Equipment $1,000,000 USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $342,000,000 USD -29%
Lessee, Operating Lease, Liability, to be Paid $133,000,000 USD -11%
Property, Plant and Equipment, Gross $88,000,000 USD 7.3%
Operating Lease, Liability, Current $13,000,000 USD 18%
Lessee, Operating Lease, Liability, to be Paid, Year Two $18,000,000 USD 5.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $17,000,000 USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $22,000,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $18,000,000 USD 5.9%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $19,000,000 USD 46%
Lessee, Operating Lease, Liability, to be Paid, Year Four $19,000,000 USD 5.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $62,000,000 USD -19%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%